View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 14, 2022

Roche’s Actemra/RoActemra obtains WHO prequalification to treat Covid-19

In addition to Covid-19 treatment, Actemra/RoActemra is intended for rheumatoid arthritis.

The World Health Organization (WHO) has granted prequalification to Roche’s intravenous (IV) dose of Actemra/RoActemra (tocilizumab) to treat severe or critical Covid-19 patients.

Actemra/RoActemra is an anti-interleukin-6 receptor (aIL-6R) treatment and obtained approval in over 110 countries.

The WHO prequalification means that Actemra/RoActemra satisfies the organisation’s safety, efficacy and quality standards to treat Covid-19 in adult patients who are taking systemic corticosteroids and need supplemental oxygen or mechanical ventilation.

Furthermore, the recognition aids buyers in low and middle-income countries to identify important therapies to enhance access to care and back improved health.

With the latest development, Actemra/RoActemra became the 12th therapy or test of Roche to obtain WHO prequalification.

In addition to Covid-19, Actemra/RoActemra is used to treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, giant cell arteritis and chimeric antigen receptor T-cell induced severe or life-threatening cytokine release syndrome. 

Roche Pharmaceuticals CEO Bill Anderson said: “People from many low- and middle-income countries continue to feel the devastating impact of Covid-19, and care needs remain unprecedented. 

“We’ve partnered with WHO and others throughout the last year to ensure that our Covid-19 medicines and tests can potentially reach more than 100 low and middle-income countries and WHO’s prequalification of Actemra/RoActemra is just one of the paths taken together to achieve this.”

Over one million severe Covid-19 patients were treated with Actemra/RoActemra since the start of the pandemic.

Last year, Actemra/RoActemra as well as the company’s Ronapreve (casirivimab plus imdevimab, REGEN-COV in the US) were recommended in Therapeutics and COVID-19 Living Guideline of the WHO.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorisation for Actemra/RoActemra for Covid-19 treatment in the European Union, in December last year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU